Clearmind Medicine (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) is a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems. The company has announced that, as part of its “Psychedelics for Alcoholism” events series, it will host Dr. Gabor Maté to discuss alcohol use disorder and how Clearmind’s candidate treatment may create a clear path to dealing with trauma. The special virtual event, slated to take place starting at 12 p.m. ET on Feb. 3, 2022, is open and free to all, with registration required. Renowned speaker and bestselling author Dr. Gabor Maté is highly sought after for his expertise on a range of topics including addiction, stress and childhood development. “We at Clearmind are committed to creating meaningful collaborations that eventually can benefit the lives of millions of people around the world including the engagement of renowned people in our fields of research,” said Dr. Adi Zuloff-Shani, Ph.D., CEO of Clearmind. “Partnering with the world-renowned expert, Dr. Gabor Maté, is a tremendous honor. The upcoming event will provide participants with valuable and fascinating insight regarding some of the most common mental health issues prevalent nowadays.”
To view the full press release, visit https://ibn.fm/IGy7C
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol CMND, the Frankfurt Stock Exchange under the symbol CWYO and on the OTC pink under the symbol CMNDF. For more information about the company, visit www.ClearmindMedicine.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork